Decision

Janssen Inc. v. Apotex Inc., 2018 FC 407 (Darunavir*)

2018-04-16

Read full decision. Automatically generated summary:

In the context of this application for a prohibition order, brought pursuant to the Patented Medicines (Notice of Compliance) Regulations, SOR/93-133 (as they existed prior to their repeal by SOR/2017-166), the Applicant and Respondent Patentee Janssen Inc. and Janssen Sciences Ireland UC bring this motion, pursuant to s. 6(7) of the Regulations, for an order compelling the Respondent, Apotex Inc., to provide non-redacted and additional portions of the Abbreviated New Drug Submissions and of the Drug Master File related to Apotex’s proposed Apo-darunavir product.

Decision relates to:

 

Canadian Intellectual Property